EUCTR2007-002548-12-BE进行中（未招募）1 期
Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditionings - Minitransplant-Random TBI vs TLI
CHU-ULG0 个研究点目标入组 60 人开始时间: 2007年12月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Hematological malignancies confirmed histologically and not rapidly progressing.
- •2. Ineligible for conventional allogeneic transplantation because of age or comorbidities.
- •3. 10/10 HLA-allele-matched related or unrelated donors.
- •4. Male or female; fertile patients must use a reliable contraception method;
- •5. Age < 75 yrs;
- •6. Informed consent given by patient or his/her guardian if of minor age.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. HIV positive;
- •2. Non-hematological malignancy(ies) (except non-melanoma skin cancer) < 3 years before nonmyeloablative HCT.
- •3. Life expectancy severely limited by disease other than malignancy;
- •4. Administration of cytotoxic agent(s) for cytoreduction” within three weeks prior to initiating the nonmyeloablative transplant conditioning (Exceptions are hydroxyurea and imatinib mesylate);
- •5. CNS involvement with disease refractory to intrathecal chemotherapy.
- •6. Terminal organ failure, except for renal failure (dialysis acceptable)
研究者
相似试验
已完成
2 期
Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditioningsminitransplantation / GvHD10024324NL-OMON32010Academisch Ziekenhuis Maastricht10
进行中（未招募）
1 期
Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditionings - Minitransplant-Random TBI vs TLIPatients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbiditiesMedDRA version: 9.1Level: LLTClassification code 10001756Term: Allogenic bone marrow transplantation therapyEUCTR2007-002548-12-NLCHU-ULG107
进行中（未招募）
不适用
Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies - NDPreparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic MalignanciesMedDRA version: 6.1Level: PTClassification code 10028228EUCTR2007-005563-10-ITFONDAZIONE NEOPLASIE SANGUE ONLUS
进行中（未招募）
不适用
Allogeneic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Refractory ?Triple Negative? Breast Cancer - NDPatients with Refractory ?Triple Negative? Breast CancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2008-006262-28-ITISTITUTO EUROPEO DI ONCOLOGIA
进行中（未招募）
1 期
Comparison of two methods for the prevention of graft-versus-host reactions after bone marrow transplantation.Hematologic malignancies treated by reduced-intensity conditioning allogeneic transplants.MedDRA version: 18.0Level: PTClassification code 10001756Term: Allogenic bone marrow transplantation therapySystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10018799Term: GVHDSystem Organ Class: 100000004870EUCTR2010-024297-19-BECHU de Liege200